Comparative analysis of the efficacy of definitive chemoradiation therapy and surgery followed by adjuvant radiation therapy in advanced-stage oral tongue cancer

Summary. The aim of the study was to compare the efficacy of definitive chemoradiation therapy (CRT) and primary surgery followed by adjuvant radiotherapy (RT) or CRT in the management of patients with stage III–IVA–B resectable oral tongue squamous cell carcinoma (OTSCC). Materials and Methods: It...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2023
Автори: Kravets, O.V., Protsyk, V.S., Burtyn, O.V., Hurianov, V.G.
Формат: Стаття
Мова:English
Опубліковано: PH Akademperiodyka 2023
Теми:
Онлайн доступ:https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-4
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Experimental Oncology

Репозитарії

Experimental Oncology
id oai:ojs2.ex.aqua-time.com.ua:article-167
record_format ojs
institution Experimental Oncology
baseUrl_str
datestamp_date 2023-10-11T16:43:26Z
collection OJS
language English
topic chemoradiotherapy
oral tongue squamous cell carcinoma
radiotherapy
surgical treatment
spellingShingle chemoradiotherapy
oral tongue squamous cell carcinoma
radiotherapy
surgical treatment
Kravets, O.V.
Protsyk, V.S.
Burtyn, O.V.
Hurianov, V.G.
Comparative analysis of the efficacy of definitive chemoradiation therapy and surgery followed by adjuvant radiation therapy in advanced-stage oral tongue cancer
topic_facet chemoradiotherapy
oral tongue squamous cell carcinoma
radiotherapy
surgical treatment
chemoradiotherapy
oral tongue squamous cell carcinoma
radiotherapy
surgical treatment
format Article
author Kravets, O.V.
Protsyk, V.S.
Burtyn, O.V.
Hurianov, V.G.
author_facet Kravets, O.V.
Protsyk, V.S.
Burtyn, O.V.
Hurianov, V.G.
author_sort Kravets, O.V.
title Comparative analysis of the efficacy of definitive chemoradiation therapy and surgery followed by adjuvant radiation therapy in advanced-stage oral tongue cancer
title_short Comparative analysis of the efficacy of definitive chemoradiation therapy and surgery followed by adjuvant radiation therapy in advanced-stage oral tongue cancer
title_full Comparative analysis of the efficacy of definitive chemoradiation therapy and surgery followed by adjuvant radiation therapy in advanced-stage oral tongue cancer
title_fullStr Comparative analysis of the efficacy of definitive chemoradiation therapy and surgery followed by adjuvant radiation therapy in advanced-stage oral tongue cancer
title_full_unstemmed Comparative analysis of the efficacy of definitive chemoradiation therapy and surgery followed by adjuvant radiation therapy in advanced-stage oral tongue cancer
title_sort comparative analysis of the efficacy of definitive chemoradiation therapy and surgery followed by adjuvant radiation therapy in advanced-stage oral tongue cancer
title_alt Comparative analysis of the efficacy of definitive chemoradiation therapy and surgery followed by adjuvant radiation therapy in advanced-stage oral tongue cancer
description Summary. The aim of the study was to compare the efficacy of definitive chemoradiation therapy (CRT) and primary surgery followed by adjuvant radiotherapy (RT) or CRT in the management of patients with stage III–IVA–B resectable oral tongue squamous cell carcinoma (OTSCC). Materials and Methods: It is a retrospective analysis of the treatment outcomes of 211 patients with stage III–IVA–B resectable OTSCC. The patients were divided into two groups depending on the treatment modality: 114 patients received surgery followed by adjuvant RT or CRT (S-RT/CRT) group; the definitive CRT group consisted of 97 patients. Results: The five-year overall survival (OS) was 57.0% in S-RT/CRT group vs 20.4% in CRT group; the five-year disease-free survival (DFS) in S-RT/CRT group was 56.5% vs 15.5%, in the CRT group. Comparison of survival curves revealed statistically significant higher OS and DFS rates in patients of S-RT/CRT group as compared with those in CRT patients (hazard ratio = 0.33 (95% confidence interval 0.23–0.47), p < 0.001 vs hazard ratio = 0.25 (95% confidence interval 0.17–0.37), p < 0.001). A multivariate analysis showed a statistically significant prognostic effect of the primary tumor extension cT4 (p = 0.004), cervical lymph node involvement cN2 (p < 0.001), cN3 (p = 0.04) and treatment modality (p < 0.001) on OS. There was also found a statistically significant prognostic effect of the primary tumor extension cT4 (p = 0.02), cervical lymph node involvement cN2 (p < 0.001) and treatment modality (p < 0.001) on DFS. 18 (15.8%) patients of S-RT/CRT group and 13 (13.4%) patients (p = 0.77) of CRT group developed mandibular osteoradionecrosis. Conclusion: Primary surgery with adjuvant RT or CRT in advanced-stage resectable OTSCC significantly increases five-year OS and DFS rates as compared to those after definitive CRT.
publisher PH Akademperiodyka
publishDate 2023
url https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-4
work_keys_str_mv AT kravetsov comparativeanalysisoftheefficacyofdefinitivechemoradiationtherapyandsurgeryfollowedbyadjuvantradiationtherapyinadvancedstageoraltonguecancer
AT protsykvs comparativeanalysisoftheefficacyofdefinitivechemoradiationtherapyandsurgeryfollowedbyadjuvantradiationtherapyinadvancedstageoraltonguecancer
AT burtynov comparativeanalysisoftheefficacyofdefinitivechemoradiationtherapyandsurgeryfollowedbyadjuvantradiationtherapyinadvancedstageoraltonguecancer
AT hurianovvg comparativeanalysisoftheefficacyofdefinitivechemoradiationtherapyandsurgeryfollowedbyadjuvantradiationtherapyinadvancedstageoraltonguecancer
first_indexed 2025-07-17T12:16:03Z
last_indexed 2025-07-17T12:16:03Z
_version_ 1837896369520508928
spelling oai:ojs2.ex.aqua-time.com.ua:article-1672023-10-11T16:43:26Z Comparative analysis of the efficacy of definitive chemoradiation therapy and surgery followed by adjuvant radiation therapy in advanced-stage oral tongue cancer Comparative analysis of the efficacy of definitive chemoradiation therapy and surgery followed by adjuvant radiation therapy in advanced-stage oral tongue cancer Kravets, O.V. Protsyk, V.S. Burtyn, O.V. Hurianov, V.G. chemoradiotherapy, oral tongue squamous cell carcinoma, radiotherapy, surgical treatment chemoradiotherapy, oral tongue squamous cell carcinoma, radiotherapy, surgical treatment Summary. The aim of the study was to compare the efficacy of definitive chemoradiation therapy (CRT) and primary surgery followed by adjuvant radiotherapy (RT) or CRT in the management of patients with stage III–IVA–B resectable oral tongue squamous cell carcinoma (OTSCC). Materials and Methods: It is a retrospective analysis of the treatment outcomes of 211 patients with stage III–IVA–B resectable OTSCC. The patients were divided into two groups depending on the treatment modality: 114 patients received surgery followed by adjuvant RT or CRT (S-RT/CRT) group; the definitive CRT group consisted of 97 patients. Results: The five-year overall survival (OS) was 57.0% in S-RT/CRT group vs 20.4% in CRT group; the five-year disease-free survival (DFS) in S-RT/CRT group was 56.5% vs 15.5%, in the CRT group. Comparison of survival curves revealed statistically significant higher OS and DFS rates in patients of S-RT/CRT group as compared with those in CRT patients (hazard ratio = 0.33 (95% confidence interval 0.23–0.47), p < 0.001 vs hazard ratio = 0.25 (95% confidence interval 0.17–0.37), p < 0.001). A multivariate analysis showed a statistically significant prognostic effect of the primary tumor extension cT4 (p = 0.004), cervical lymph node involvement cN2 (p < 0.001), cN3 (p = 0.04) and treatment modality (p < 0.001) on OS. There was also found a statistically significant prognostic effect of the primary tumor extension cT4 (p = 0.02), cervical lymph node involvement cN2 (p < 0.001) and treatment modality (p < 0.001) on DFS. 18 (15.8%) patients of S-RT/CRT group and 13 (13.4%) patients (p = 0.77) of CRT group developed mandibular osteoradionecrosis. Conclusion: Primary surgery with adjuvant RT or CRT in advanced-stage resectable OTSCC significantly increases five-year OS and DFS rates as compared to those after definitive CRT. Summary. The aim of the study was to compare the efficacy of definitive chemoradiation therapy (CRT) and primary surgery followed by adjuvant radiotherapy (RT) or CRT in the management of patients with stage III–IVA–B resectable oral tongue squamous cell carcinoma (OTSCC). Materials and Methods: It is a retrospective analysis of the treatment outcomes of 211 patients with stage III–IVA–B resectable OTSCC. The patients were divided into two groups depending on the treatment modality: 114 patients received surgery followed by adjuvant RT or CRT (S-RT/CRT) group; the definitive CRT group consisted of 97 patients. Results: The five-year overall survival (OS) was 57.0% in S-RT/CRT group vs 20.4% in CRT group; the five-year disease-free survival (DFS) in S-RT/CRT group was 56.5% vs 15.5%, in the CRT group. Comparison of survival curves revealed statistically significant higher OS and DFS rates in patients of S-RT/CRT group as compared with those in CRT patients (hazard ratio = 0.33 (95% confidence interval 0.23–0.47), p < 0.001 vs hazard ratio = 0.25 (95% confidence interval 0.17–0.37), p < 0.001). A multivariate analysis showed a statistically significant prognostic effect of the primary tumor extension cT4 (p = 0.004), cervical lymph node involvement cN2 (p < 0.001), cN3 (p = 0.04) and treatment modality (p < 0.001) on OS. There was also found a statistically significant prognostic effect of the primary tumor extension cT4 (p = 0.02), cervical lymph node involvement cN2 (p < 0.001) and treatment modality (p < 0.001) on DFS. 18 (15.8%) patients of S-RT/CRT group and 13 (13.4%) patients (p = 0.77) of CRT group developed mandibular osteoradionecrosis. Conclusion: Primary surgery with adjuvant RT or CRT in advanced-stage resectable OTSCC significantly increases five-year OS and DFS rates as compared to those after definitive CRT. PH Akademperiodyka 2023-05-31 Article Article application/pdf https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-4 10.32471/exp-oncology.2312-8852.vol-42-no-3.14873 Experimental Oncology; Vol. 42 No. 3 (2020): Experimental Oncology; 228-232 Експериментальна онкологія; Том 42 № 3 (2020): Експериментальна онкологія; 228-232 2312-8852 1812-9269 10.32471/exp-oncology.2312-8852.vol-42-no-3 en https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-4/2020-3-4 Copyright (c) 2023 Experimental Oncology https://creativecommons.org/licenses/by-nc/4.0/